About uniQure
uniQure is a world leader in the development of human gene-based therapies. UniQure's gene therapy products in development include hemophilia B, acute intermittent porphyria, Parkinson's disease and Sanfilippo syndrome type B. By using adeno-associated viral (AAV) derived vectors as the transport vehicle of choice for therapeutic genes, the company has succeeded in creating and validating the world's first stable and scalable production platform.
uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two leading life sciences venture capital firms in the Netherlands.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Biotechnology
